Novel approaches to therapy for systemic lupus erythematosus: update 2005

References

• Zandman-Goddard G, Shoenfeld Y. Novel approaches to therapy for systemic lupus erythematosus. Eur. J. Int. Med.11(3), 130–134 (2000).
   Google Scholar
• Zandman-Goddard G, Shoenfeld Y. Novel approaches to therapy for SLE. Clin. Rev. Allergy Immunol. 25(1), 105–112 (2003).
   Google Scholar
• Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol. 28(4), 780–785 (2001).
   PubMed Web of Science ®Google Scholar
• Levy RA, Vilela VS, Cataldo MJ et al. Hydroxychloroquine in lupus pregnancy: double-blind and placeba controlled study. Lupus 10(6), 401–404 (2001).
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Duhaut P et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 48(11), 3207–3211 (2003).
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Amoura Z, Huong du LT, Lechat P, Piette JC. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4(2), 111–115 (2005).
   PubMed Web of Science ®Google Scholar
• Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J. Rheumatol. 27(6), 1429–1433 (2000).
   PubMed Web of Science ®Google Scholar
• Karim MY, Ruiz-Irastorza G, Khamashta MA, Hughes GR. Update on therapy-thalidomide in the treatment of lupus. Lupus 10(3), 188–192 (2001).
   PubMed Web of Science ®Google Scholar
• Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin. Drug Saf. 3(1), 47–56 (2004).
   PubMedGoogle Scholar
• Pelle MT, Werth VP. Thalidomide in cutaneous lupus erythematosus. Am. J. Clin. Dermatol. 4(6), 379–387 (2003).
   PubMed Web of Science ®Google Scholar
• Housman TS, Jorizzo JL, McCarty MA, Grummer SE, Fleischer AB Jr, Sutej PG. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch. Dermatol. 139(1), 50–54 (2003).
   PubMedGoogle Scholar
• Wallace DJ. Management of lupus erythematosus: recent insights. Curr. Opin. Rheumatol. 14(3), 212–219 (2002).
   PubMedGoogle Scholar
• Wong JM, Esdaile JM. Methotrexate in systemic lupus erythematosus. Lupus 14(2), 101–105 (2005).
   PubMed Web of Science ®Google Scholar
• Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 12, 935–942 (2003).
   Google Scholar
• Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10(7), 480–483 (2001).
   PubMed Web of Science ®Google Scholar
• Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13(8), 601–604 (2004).
   PubMed Web of Science ®Google Scholar
• Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(11), 2924–2927 (2002).
   PubMed Web of Science ®Google Scholar
• Petri MA, Mease PJ, Merrill JT et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 50, 2858–2868 (2004).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Elliot D, Powell M, Cho S, Hsiu J, Wishnewsky A. Dehydroepiandrosterone improves cognitive function in patients with systemic lupus erythematosus: results of a double-blinded, placebo-controlled pilot study. Lupus 10(Suppl.), S51 (2001).
   Google Scholar
• Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. Arthritis Rheum. 50(11), 3591–3595 (2004).
   PubMedGoogle Scholar
• Chang DM, Chu SJ, Chen HC, Kuo SY, Lai J. Dehydroepiandrosterone suppresses interleukin-10 synthesis in women with systemic lupus erythematosus. Ann. Rheum. Dis. 63(12), 1623–1626 (2004).
   PubMed Web of Science ®Google Scholar
• Houssiau FA. Cyclophosphamide in lupus nephritis. Lupus 14(1), 53–58 (2005).
   PubMedGoogle Scholar
• Balow JE, Boumpas DT, Fessler BJ, Austin HA III. Management of lupus nephritis. Kidney Int.49(Suppl.), S88–S92 (1996).
   Google Scholar
• Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. 135(4), 248–257 (2001).
   PubMed Web of Science ®Google Scholar
• Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 46(4), 995–1002 (2002).
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46(8), 2121–2131 (2002).
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 50(12), 3934–3940 (2004).
   PubMed Web of Science ®Google Scholar
• Yee CS, Gordon C, Dostal C et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann. Rheum. Dis. 63(5), 525–529 (2004).
   PubMed Web of Science ®Google Scholar
• Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose iv. cyclophosphamide and prednisolone (pilot study). Lupus 12(1), 3–7 (2003).
   PubMed Web of Science ®Google Scholar
• Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin. Rheumatol. 23(5), 395–399 (2004).
   PubMed Web of Science ®Google Scholar
• Sanna G, Khamashta MA. Low-dose pulse cyclophosphamide in the treatment of neuropsychiatric lupus. Lupus 12(1), 1–2 (2003).
   Google Scholar
• Bodani M, Kopelman MD. A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus. Lupus 12(12), 947–949 (2003).
   Google Scholar
• Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 10(3), 152–153 (2001).
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343(16), 1156–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Aranow C. Mycophenolate mofetil in lupus nephritis. Lupus 14(1), 59–64 (2005).
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Shoenfeld Y. Mycophenolate mofetil in animal models of autoimmune disease. Lupus 14(Suppl.), 12–16 (2005).
   PubMed Web of Science ®Google Scholar
• Chan TM, Tse KC, Tang C, Mok MY, Li FK, Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16(4), 1076–1084 (2005).
   PubMed Web of Science ®Google Scholar
• Ye Z, Tan YH, Hong XP, Feng XX, Xiano XL. MMF vs. CTX in the treatment of severe SLE patients. Lupus 10(Suppl.), 99 (2001).
   Google Scholar
• Hu W, Liu Z, Chen H et al. Mycophenolate mofetil vs. cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin. Med. J. (Engl.) 115(5), 705–709 (2002).
   PubMed Web of Science ®Google Scholar
• Ding L, Zhao M, Zou W, Liu Y, Wang H. Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. Lupus 13(2), 113–118 (2004).
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Aranow C, Buyon J et al. A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results. Arthritis Rheum. 48(Suppl.), 647 (2003).
   Google Scholar
• Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350(10), 971–980 (2004).
   PubMed Web of Science ®Google Scholar
• Kingdon EJ, McLean AG, Psimenou E et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 10(9), 606–611 (2001).
   PubMedGoogle Scholar
• Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology 43(3), 377–380 (2004).
   PubMed Web of Science ®Google Scholar
• Spetie DN, Tang Y, Rovin BH et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 66(6), 2411–2415 (2004).
   PubMed Web of Science ®Google Scholar
• Karim MY, Alba P, Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 41(8), 876–882 (2002).
   PubMed Web of Science ®Google Scholar
• Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J. Rheumatol. 30(7), 1508–1512 (2003).
   PubMed Web of Science ®Google Scholar
• Jayne D, Tyndall A. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13(5), 359–365 (2004).
   PubMedGoogle Scholar
• Jayne D, Passweg J, Marmont A et al. European Group for Blood and Marrow Transplantation; European League Against Rheumatism Registry. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13(3), 168–176 (2004).
   PubMed Web of Science ®Google Scholar
• Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 48(1), 166–173 (2003).
   PubMed Web of Science ®Google Scholar
• Willeke P, Schotte H, Erren M et al. Concomitant reduction of disease activity and IL-10 secreting peripheral blood mononuclear cells during immunoadsorption in patients with active systemic lupus erythematosus. Cell. Mol. Biol. 48(3), 323–329 (2002).
   Google Scholar
• Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum. 44(8), 1962–1963 (2001).
   PubMed Web of Science ®Google Scholar
• Zouali M. B-cell diversity and longevity in systemic autoimmunity. Mol. Immunol. 38(12–13), 895–901 (2002).
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Shoenfeld Y. Therapy with biologic agents in SLE. APLAR J. Rheumatol. 7(1), 79–82 (2004).
   Google Scholar
• Grillo-Lopez A. Rituximab: an insider’s historical perspective. Semin. Oncol. 6(Suppl. 12), 9–16 (2000).
   Google Scholar
• Edwards JC, Szczepanski L, Scechinski J et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572–2581 (2004).
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D et al. B-cell depletion as novel treatment for systemic lupus erythematosus. A Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50(8), 2580–2589 (2004).
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Capione A et al. Rituximab improves peripheral B-cell abnormalities in human systemic erythematosus. Arthritis Rheum. 50(11), 3580–3590 (2004).
   PubMed Web of Science ®Google Scholar
• Albert DA, Khan SR, Stansberry J, Tsai D, Eisenberg RA. A Phase I trial of rituximab (anti CD20) for treatment of systemic lupus. American College of Rheumatology Annual Meeting 2003. (Late breaking) Abstract 9.
   Google Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B-lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46(10), 2673–2677 (2002).
   PubMed Web of Science ®Google Scholar
• Tahir H, Isenberg DA. Novel therapies in lupus nephritis. Lupus 14(1), 77–82 (2005).
   Google Scholar
• Leandro MJ, Eherenstein MR, Edwards JC Mason J, Cambridge G, Isenberg DA. Treatment of refractory lupus nephritis with B-lymphocyte depletion. Arthritis Rheum. 48(Suppl. 9), S378 (2002).
   Google Scholar
• Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by downregulation of the T-cell costimulatory molecule CD40 ligand. An open trial. Arthritis Rheum. 52(2), 501–513 (2005).
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Fujii K, Saito K et al. Downregulation of CD40 and CD80 on B-cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology44(2), 176–182 (2005).
   PubMed Web of Science ®Google Scholar
• Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 12(10), 779–782 (2003).
   PubMed Web of Science ®Google Scholar
• Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA. Humanized antiCD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rhematology (Oxford) 44(4), 561–562 (2005).
   PubMed Web of Science ®Google Scholar
• Baker K, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B-lymphocyte stimulation. Arthritis Rheum. 48(11), 3253–3265 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B-lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166(1), 6–10 (2001).
   PubMed Web of Science ®Google Scholar
• Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B-lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44(6), 1313–1319 (2001).
   PubMed Web of Science ®Google Scholar
• Petri M, Stohl W, Chatham W et al. BlyS plasma concentrations correlate with disease activity and levels of antidsDNA autoantibodies and immunoglobulins (IG) in a SLE observational study. Arthritis Rheum. 48(Suppl.), 655 (2003).
   Google Scholar
• Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28(2), 257–265 (2001).
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48(2), 442–454 (2003).
   Google Scholar
• Cardiel MH. Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. Expert Opin. Investig. Drugs 14(1), 77–88 (2005).
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T-cell costimulation with antiCD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(12), 3251–3258 (2002).
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D, IDEC-131 lupus study group. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. 28(1), 95–101 (2001).
   PubMed Web of Science ®Google Scholar
• Liossis SN, Sfikakis PP. Costimulation blockade in the treatment of rheumatic diseases. BioDrugs 18(2), 95–102 (2004).
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Rauova L, Gilburd B et al. Efficacy of IVIG affinity-purified antidouble-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol 14(11), 1303–1311 (2002).
   PubMed Web of Science ®Google Scholar
• Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Semin. Arthritis Rheum. 34(3), 593–601(2004).
   PubMed Web of Science ®Google Scholar
• Levy Y, Sherer Y, George J et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin. Arthritis Rheum. 29(5), 321–327 (2000).
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43(8), 1790–1780 (2000).
   PubMed Web of Science ®Google Scholar